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Middle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor. Mouse
DPP4 (mDPP4) does not support MERS-CoV entry; however, changes at positions 288 and 330 can confer permissivity. Position
330 changes the charge and glycosylation state of mDPP4.We show that glycosylation is a major factor impacting DPP4 receptor
function. These results provide insight into DPP4 species-specific differences impactingMERS-CoV host range andmay inform
MERS-CoVmouse model development.
Coronaviruses are a diverse family of single-stranded, positive-sense RNA viruses that have frequently undergone host range
expansion events. While coronaviruses have expanded their host
range into humans multiple times over the course of their evolu-
tionary history, two recent events have resulted in the emergence
of highly pathogenic epidemic strains. First, severe acute respira-
tory syndrome coronavirus (SARS-CoV) emerged into the human
population in 2003 and infected over 8,000 people before finally
being contained by aggressive public health intervention strate-
gies. More recently in 2012, Middle East respiratory syndrome
coronavirus (MERS-CoV) emerged from its zoonotic host species
into humans, resulting in severe disease and a 38%mortality rate.
MERS-CoV likely originated from a bat reservoir species, as evi-
denced by the identification of closely related MERS-CoV-like
viruses in bats (1, 2), although current hypotheses suggest that a
camel intermediate host also played an important role in the host
range expansion event.
The functional receptor forMERS-CoVwas recently identified
as dipeptidyl peptidase 4 (DPP4) (3). Interestingly, while MERS-
CoV can utilize human, bat, and camel DPP4 (14, 15), traditional
small animal models are nonpermissive, including mice (4, 5),
ferrets (6), and hamsters (7, 14). The relevance of MERS-CoV as
an emerging pathogen and the importance of small animalmodels
for studying pathogenesis and for developing vaccines and thera-
peutics led us to identify the determinants of interactions between
the MERS-CoV receptor binding domain (RBD) and mouse
DPP4 (mDPP4). Interactions between DPP4 and the MERS-CoV
RBD are primarily restricted to blades IV and V of the DPP4 N-
terminal -propeller domain (8, 9). Recently, we found that two
key residues in mDPP4 (A288L and T330R) could permit infec-
tion by MERS-CoV when mutated to the human DPP4 (hDPP4)
amino acids (4). These residues lie within blades IV and V of the
-propeller domain (8, 9). The importance of A288L can be un-
derstood by recognizing that there is a strong hydrophobic region
in the MERS-CoV RBD that engages the equivalent hDPP4 resi-
due (L294) (9). In fact, all permissive DPP4 orthologs have a leu-
cine residue at this site (i.e., bat, camel, human, and marmoset).
This interaction, however, is altered in mDPP4, potentially mak-
ing this hydrophobic region less amenable to interacting with the
MERS-CoV RBD.
On blade IV, the T330R substitution in mDPP4 regulates two
potentially critical virus-host cell receptor interaction events.
First, arginine 330 provides a highly conserved charge that is pres-
ent in all known permissive hosts but missing from all known
nonpermissive hosts (Fig. 1A). In hDPP4, the interaction between
this residue (R336, relative to hDPP4 numbering) and theMERS-
CoV RBD Y499 has been previously noted as a key interaction (8,
9). The absence of this interaction could be a primary factor be-
hind the lack of permissivity of mDPP4, as well as other nonper-
missive DPP4 orthologs. Second, the T330Rmutation knocks out
an NXT glycosylation motif in mDPP4. Western blot analysis is
consistentwith the loss of glycosylation at this site, as evidenced by
an2.5-kDa downward shift in the mDPP4 T330R mutant (Fig.
1B). Considering these two potentially important effects, we hy-
pothesized that either the introduction of the conserved charge or
the removal of glycosylation was crucial for regulating mDPP4
permissivity to MERS-CoV infection.
To test the impact of glycosylation versus charge on the ability
of mDPP4 to support infection by MERS-CoV, we generated a
panel of DPP4 mutants (Fig. 1C and D) contained within the
945RRE expression vector, a lentiviral vector derived from
pTK945. DPP4 constructs were expressed in human embryonic
kidney 293T (HEK 293T) cells that lack detectable expression of
endogenous hDPP4 (10). At 18 h posttransfectionwith 3g of the
DPP4 expression plasmid, cells were infected with rMERS-CoV-
RFP which encodes tomato red fluorescent protein in place of
ORF5 (11). Cells were imaged 24 h postinfection to assess the
number of positive cells as a readout for MERS-CoV infection.
A set of hDPP4 mutants were generated and assayed for per-
missivity to MERS-CoV infection in order to first assess the im-
portance of glycosylation versus charge in the human context.We
generated two mutants: one that included a glycosylation site and
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one that removed the charge. First, we swapped the three residues
of theNLTmDPP4 putative glycosylation site with residues 334 to
336 of hDPP4 (hDPP4gly). This addition shows a severe reduc-
tion in infection (Fig. 2A and B), with an upward shift in the
Western blot band consistent with successful introduction of the
glycosylation site (Fig. 2C). However, this mutation impacts both
the glycosylation site and the charged 336 residue (aligning to
residue 330 in mDPP4) (Fig. 1A). Therefore, our second mutant
FIG 1 Is charge or glycosylation important for mediating mouse DPP4 permissivity? (A) MEGA6 protein sequence alignment of DPP4 for various permissive
(human, camel, and bat) and nonpermissive (mouse, ferret, hamster, and guinea pig) species, visualized in GeneDoc. Residue numbers are relative to mDPP4.
Themutation T330R inmDPP4 introduces a conserved positive charge for permissive hosts but also knocks out a glycosylation site. NCBI accession numbers are
as follows: human, NP_001926.2; camel, AIG55259; bat, AGF80256.1; mouse, NP_034204.1; ferret, ABC72084.1; hamster, AIG55262.1; guinea pig,
XP_003478612.2. (B) The downward shift in the mDPP4 T330R band is consistent with the removal of glycosylation. Western blot protocol followed that
described by Cockrell et al. (4). (C) Structure of hDPP4 (yellow) complexed with the MERS-RBD (red) (PDB code 4L72) visualized using PyMOL Molecular
Graphics System, version 1.6.0.0 (Schrodinger, LLC).mDPP4 (blue), threaded through i-TASSER (13), is overlaid to show the keymutations: A288L, T330R, and
N328A. Blue indicates wild-type mDPP4 residues, while orange indicates the human amino acid identity. (D) DPP4 constructs used. Whether they are
glycosylated at residue 328 and whether the conserved positive arginine is present at residue 330 (numbered relative to mDPP4) are also shown.
FIG 2 Glycosylation can act to dramatically reduce infection by MERS-CoV. (A) HEK 293T cells were transfected with each DPP4 construct and infected with
rMERS-CoV-RFP at a multiplicity of infection (MOI) of 1 at18 h posttransfection. At24 h postinfection, cells were imaged. (B) Cells were transfected as
described for panel A and infected with rMERS-CoV-RFP at the following MOIs: hDPP4 and hDPP4 R336T, 0.001; no DPP4 and hDPP4gly, 0.1. At 24 h
postinfection, cells were counted based on red fluorescence, and values were normalized to anMOI of 0.1. Values represent 3 replicates. All mutants have levels
that are statistically greater than those obtained with no DPP4, and all other pairwise comparisons are also statistically significant (*, P 0.05; Student’s t test).
(C) Western blot analysis for MERS nucleocapsid (N) protein, DPP4, and actin as a loading control. The Western blot protocol followed that described by
Cockrell et al. (4).
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contains the R336Tmutation by itself, which removes the positive
charge without introducing glycosylation. While we did observe a
decrease in infection, it was not comparable in magnitude to the
decrease seen when glycosylation was included (Fig. 2A and B),
suggesting that the presence of a positively charged residue at po-
sition 336 is not essential for hDPP4-mediated MERS-CoV infec-
tion. Additionally, the presence of glycosylation does not impact
the ability of hDPP4gly to be expressed on the cell surface (Fig.
3). These results show that glycosylation can act to inhibit infec-
tion by MERS-CoV and that the positive charge is not a crucial
interaction in the context of hDPP4.
In order to directly assess the relative contribution of charge
versus glycosylation in the context of mDPP4, we evaluated
whether the presence of glycosylation or charge at the 330 site
regulates mDPP4 receptor activity. For these studies, mutations
were evaluated singly and in the presence of the secondary muta-
tion (A288L), which is essential for high levels of MERS-CoV re-
ceptor activity. Importantly, introduction of the charged residue
at 330 simultaneously destroys the glycosylation site, preventing
us from testing whether the presence of the charged residue at 330
can enhance mDPP4 receptor activity in the presence of a glyco-
sylation site. However, it is possible to remove the glycosylation
site without introducing a charged residue with the mutation
N328A, which disrupts the N of the NXT motif (Fig. 1A and D).
When we assessed the N328A mutant in the context of the A288L
background, we observed high levels of infection (Fig. 4A) that are
not statistically different from those obtained with mDPP4
A288L, T330R (Fig. 4B). Both glycosylation knockout mutants
have levels that are statistically greater than mDPP4 but statisti-
cally less than hDPP4 (Fig. 4B). All mutants containing the T330R
or N328A mutation show an 2.5-kDa downward shift in the
Western blot, consistent with the loss of glycosylation (Fig. 4C).
Importantly, surface staining formDPP4 and hDPP4 showed that
all derivatives of the DPP4 receptors are expressed at the cell sur-
FIG 3 DPP4 and mutant variants are expressed on the surfaces of cells, visible by immunofluorescence. Cells were transfected as described in the legend to Fig.
2A, fixed, and probed with primary goat-anti-DPP4 polyclonal antibody (R&D Systems) at 1:50 and secondary donkey anti-goat IgG–Alexa Fluor 488 (Life
Technologies) at 1:500. Cells were imaged at 40 for DAPI (30-ms exposure) and DPP4 (160-ms exposure).
FIG 4 Glycosylation, rather than charge, is a key determinant of mouse DPP4 permissivity to MERS-CoV. (A) Cells were transfected and infected following the
protocol detailed in the legend to Fig. 2A.NeithermDPP4N328AnormDPP4T330R can confer permissivity toMERS-CoV; however, both result in strong levels
of infectionwhen coupledwithA288L. (B)Red cell countswere calculated as for Fig. 2Bwith the followingMOIs: hDPP4, 0.001;mDPP4,mDPP4A288L,mDPP4
N328A,mDPP4 T330R, and noDPP4, 0.1; mDPP4 A288L, N328A andmDPP4 A288L, T330R, 0.01. Values for all DPP4 constructs are significantly greater than
those for no DPP4 and mDPP4 (*, P 0.05; Student’s t test) and significantly less than that for hDPP4 (, P 0.05; Student’s t test); however, the values for
mDPP4 A288L, N328A and mDPP4 A288L, T330R are not statistically different from each other (n.s. [not significant], P 0.05; Student’s t test). (C) Western
blot analysis for MERS nucleocapsid (N) protein, DPP4, and actin as a loading control. TheWestern blot protocol followed that described by Cockrell et al. (4).
Peck et al.
4698 jvi.asm.org April 2015 Volume 89 Number 8Journal of Virology
face and available to interact with the MERS-CoV RBD (Fig. 3).
Together, these results indicate that removal of the glycosylation
site, rather than addition of the charged residue at position 330, is
responsible for regulating the ability of MERS-CoV to utilize
mDPP4 as a functional receptor. The secondarymutation, A288L,
also plays an important role inMERS-CoVpermissivity due to the
fact that high levels of infection are seen only when the glycosyla-
tionmutations are combinedwith theA288L substitution (Fig. 4A
and B). Together, this suggests that while glycosylation is an im-
portant barrier, its removal is not sufficient to permit infection in
the absence of the A-to-L modification at position 288.
The importance of glycosylation in the interactions between
coronaviruses and host cell receptors was recognized previously.
For example, the introduction of a glycosylation site into human
aminopeptidase N (APN) prevents human coronavirus 229E
from utilizing it as a receptor (12). For MERS-CoV, it is possible
that glycosylation can act as a broader determinant of DPP4-me-
diated host range, since other nonpermissive hosts (i.e., ferrets
and hamsters) also have a nonconserved glycosylation site in the
region of DPP4 that interacts with the MERS-RBD (Fig. 1A). In
the context of a small animal model, the presence of the glycosy-
lation site at position 330 may sterically hinder multiple interact-
ing residues between the MERS-CoV RBD and mDPP4, compli-
cating the generation of amouse-adapted strain. Therefore, itmay
be necessary to partially or fully humanize mDPP4 to achieve in
vivo MERS-CoV replication. Additionally, the finding that
changes in both blades of mDPP4 are crucial for mediating per-
missivity to MERS-CoV (Fig. 4A) has two major implications.
First, it may help inform future studies in other nonpermissive
hosts, particularly since single amino acid changes have not re-
sulted in successful infections (e.g., ferrets) (data not shown). Sec-
ond, it suggests that circulating MERS-like coronaviruses cannot
expand their host range into mice and possibly other rodent spe-
cies with just one change. Rather, extensive remodeling of the
MERS-CoV RBD is likely required for it to successfully utilize
nonpermissive DPP4 orthologs as receptors, especially if glycosy-
lation acts to block infection in these alternate species. Presum-
ably, the modifications that would allow the MERS-CoV RBD to
utilize mDPP4 and other orthologs would likely attenuate or even
ablate its ability to utilize hDPP4. Overall, by understanding the
biochemical determinants that mediate MERS-CoV utilization of
DPP4 orthologs, we can begin to characterize the selective pres-
sures leading up to host range expansion events, with the broader
goal of being able to predict future emergences.
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